首页 > 最新文献

CNS Oncology最新文献

英文 中文
Small cell glioblastoma multiforme: a case series and clinicopathological update. 多形性小细胞胶质母细胞瘤:病例系列和临床病理进展。
Q1 Medicine Pub Date : 2020-12-01 Epub Date: 2020-12-07 DOI: 10.2217/cns-2020-0016
Arun Kumar Yadav, Renu Madan, Debajyoti Chatterjee, Shalin Dhiman, Shikha Goyal, Narendra Kumar, Sushanta Kumar Sahoo
Small cell glioblastoma (scGBM) is a rare histological variant of classical glioblastoma (GBM). Presence of necrosis and microvascular proliferation is not essential for the diagnosis. It is thought to have more aggressive behavior as compared with classical GBM; however, because of its rarity standard treatment guidelines are not available. Adjuvant treatment for these cancers consists of postoperative radiotherapy with concurrent and maintenance temozolomide similar to classical GBM. Here we present a case series of five small cell glioblastoma patients along with the clinical-pathological review.
小细胞胶质母细胞瘤(scGBM)是典型胶质母细胞瘤(GBM)的一种罕见的组织学变异。坏死和微血管增生的存在并不是诊断的必要条件。与经典GBM相比,它被认为具有更强的攻击性行为;然而,由于其罕见性,尚无标准治疗指南。这些癌症的辅助治疗包括与经典GBM类似的术后放疗同时和维持替莫唑胺。在此,我们报告5例小细胞胶质母细胞瘤患者的临床病理资料。
{"title":"Small cell glioblastoma multiforme: a case series and clinicopathological update.","authors":"Arun Kumar Yadav, Renu Madan, Debajyoti Chatterjee, Shalin Dhiman, Shikha Goyal, Narendra Kumar, Sushanta Kumar Sahoo","doi":"10.2217/cns-2020-0016","DOIUrl":"https://doi.org/10.2217/cns-2020-0016","url":null,"abstract":"Small cell glioblastoma (scGBM) is a rare histological variant of classical glioblastoma (GBM). Presence of necrosis and microvascular proliferation is not essential for the diagnosis. It is thought to have more aggressive behavior as compared with classical GBM; however, because of its rarity standard treatment guidelines are not available. Adjuvant treatment for these cancers consists of postoperative radiotherapy with concurrent and maintenance temozolomide similar to classical GBM. Here we present a case series of five small cell glioblastoma patients along with the clinical-pathological review.","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/cns-2020-0016","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38681700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Time to treatment initiation and outcomes in high-grade glioma patients in rehabilitation: a retrospective cohort study. 康复治疗中高级别胶质瘤患者的治疗起始时间和预后:一项回顾性队列研究。
Q1 Medicine Pub Date : 2020-12-01 Epub Date: 2020-10-28 DOI: 10.2217/cns-2020-0018
Kwanza T Warren, Linxi Liu, Yang Liu, Myla S Strawderman, Ali H Hussain, Heather M Ma, Michael T Milano, Nimish A Mohile, Kevin A Walter

Aims: To investigate wait time (WT) for chemoradiation and survival in post-op high-grade glioma (HGG) patients admitted to inpatient rehabilitation compared with those discharged home. Materials & methods: A total of 291 HGG patients (14.4% grade III and 84.9% grade IV) were included in this retrospective cohort study. Patients were grouped by disposition following surgery. Results: Median length of stay was longer in acute inpatient rehabilitation facility (AIRF) patients (10d) compared with patients discharged home (3d). AIRF admission was associated with higher odds of excessive treatment delay. Median survival for AIRF patients less than for patients discharged home (42.9 vs 72.71 weeks). WT was not associated with survival even after adjusting for prognostic factors. Conclusion: HGG patients discharged to rehabilitation facilities have longer length of stay, longer WT and shorter survival compared with patients discharged home.

目的:比较住院康复的高级别胶质瘤(HGG)术后患者与出院患者的放化疗等待时间和生存率。材料与方法:本回顾性队列研究共纳入291例HGG患者(III级14.4%,IV级84.9%)。患者按术后处置进行分组。结果:急性住院康复设施(AIRF)患者的中位住院时间(10d)比出院回家的患者(3d)更长。AIRF入院与过度治疗延迟的几率较高相关。AIRF患者的中位生存期低于出院患者(42.9周vs 72.71周)。即使在调整预后因素后,WT也与生存率无关。结论:HGG患者在康复机构的住院时间更长,WT更长,生存时间更短。
{"title":"Time to treatment initiation and outcomes in high-grade glioma patients in rehabilitation: a retrospective cohort study.","authors":"Kwanza T Warren,&nbsp;Linxi Liu,&nbsp;Yang Liu,&nbsp;Myla S Strawderman,&nbsp;Ali H Hussain,&nbsp;Heather M Ma,&nbsp;Michael T Milano,&nbsp;Nimish A Mohile,&nbsp;Kevin A Walter","doi":"10.2217/cns-2020-0018","DOIUrl":"https://doi.org/10.2217/cns-2020-0018","url":null,"abstract":"<p><p><b>Aims:</b> To investigate wait time (WT) for chemoradiation and survival in post-op high-grade glioma (HGG) patients admitted to inpatient rehabilitation compared with those discharged home. <b>Materials & methods:</b> A total of 291 HGG patients (14.4% grade III and 84.9% grade IV) were included in this retrospective cohort study. Patients were grouped by disposition following surgery. <b>Results:</b> Median length of stay was longer in acute inpatient rehabilitation facility (AIRF) patients (10d) compared with patients discharged home (3d). AIRF admission was associated with higher odds of excessive treatment delay. Median survival for AIRF patients less than for patients discharged home (42.9 vs 72.71 weeks). WT was not associated with survival even after adjusting for prognostic factors. <b>Conclusion:</b> HGG patients discharged to rehabilitation facilities have longer length of stay, longer WT and shorter survival compared with patients discharged home.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/cns-2020-0018","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38541957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Endocrine therapy for the treatment of leptomeningeal carcinomatosis in luminal breast cancer: a comprehensive review. 内分泌疗法治疗腔内乳腺癌轻脑膜癌:综合综述。
Q1 Medicine Pub Date : 2020-12-01 Epub Date: 2020-10-20 DOI: 10.2217/cns-2020-0023
Leonor Fernandes, Leonor Vasconcelos de Matos, Débora Cardoso, Marlene Saraiva, Renata Medeiros-Mirra, Andreia Coelho, Helena Miranda, Ana Martins

Leptomeningeal disease (LMD) represents a devastating complication of advanced breast cancer (ABC), with survival of <5 months with multimodal treatment. The role of endocrine therapy (ET), due to its favorable toxicity profile and first-line indication in luminal ABC, appears promising in the setting of LMD, where symptom stabilization and quality-of-life preservation are the main goals; however, evidenced-based data are lacking. We conducted a thorough review of published evidence, aiming to investigate the role of ET in LMD treatment in luminal ABC. Twenty-one of 342 articles, evaluating 1302 patients, met inclusion criteria. ET use was rarely reported. New targeted agents show CNS activity. Research is lacking on the role of ET and targeted agents in BC-LMD treatment.

轻脑膜病(LMD)是晚期乳腺癌(ABC)的一种毁灭性并发症,其生存率为
{"title":"Endocrine therapy for the treatment of leptomeningeal carcinomatosis in luminal breast cancer: a comprehensive review.","authors":"Leonor Fernandes,&nbsp;Leonor Vasconcelos de Matos,&nbsp;Débora Cardoso,&nbsp;Marlene Saraiva,&nbsp;Renata Medeiros-Mirra,&nbsp;Andreia Coelho,&nbsp;Helena Miranda,&nbsp;Ana Martins","doi":"10.2217/cns-2020-0023","DOIUrl":"https://doi.org/10.2217/cns-2020-0023","url":null,"abstract":"<p><p>Leptomeningeal disease (LMD) represents a devastating complication of advanced breast cancer (ABC), with survival of <5 months with multimodal treatment. The role of endocrine therapy (ET), due to its favorable toxicity profile and first-line indication in luminal ABC, appears promising in the setting of LMD, where symptom stabilization and quality-of-life preservation are the main goals; however, evidenced-based data are lacking. We conducted a thorough review of published evidence, aiming to investigate the role of ET in LMD treatment in luminal ABC. Twenty-one of 342 articles, evaluating 1302 patients, met inclusion criteria. ET use was rarely reported. New targeted agents show CNS activity. Research is lacking on the role of ET and targeted agents in BC-LMD treatment.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/cns-2020-0023","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38510278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Intermixed arteriovenous malformation and hemangioblastoma: case report and literature review. 动静脉畸形和血管母细胞瘤混合瘤:病例报告和文献综述。
Q1 Medicine Pub Date : 2020-12-01 Epub Date: 2020-11-27 DOI: 10.2217/cns-2020-0021
Vincent Healy, Philip J O'Halloran, Mohammed B Husien, Ciaran Bolger, Michael Farrell

We report the third presentation of an intermixed arteriovenous malformation and hemangioblastoma. The rare occurrence of the diagnostic histologic features of both a neoplasm and vascular malformation in a single lesion is more common in gliomas, as angioglioma, and is termed an 'intermixed' lesion. We review the literature concerning the developmental biology of each lesion, and potential interplay in the formation of an intermixed vascular neoplasm and vascular malformation. The roles of cellular origin, genetic susceptibility, favourable microenvironment, altered local gene expression and key regulatory pathways are reviewed. Our review supports angiography and genetic profiling in intermixed lesions to inform management strategies. Consideration should be given to multimodality therapeutic interventions as required, including microsurgical resection, stereotactic radiosurgery and further research to exploit emerging molecular targets.

我们报告了第三例动静脉畸形和血管母细胞瘤混合瘤。在单一病变中同时出现肿瘤和血管畸形的组织学诊断特征的情况非常罕见,这种情况在胶质瘤(如血管胶质瘤)中更为常见,被称为 "混合 "病变。我们回顾了有关每种病变的发育生物学特性以及血管肿瘤和血管畸形混杂形成的潜在相互作用的文献。我们回顾了细胞起源、遗传易感性、有利的微环境、局部基因表达改变和关键调控途径的作用。我们的综述支持对混合性病变进行血管造影和基因分析,为管理策略提供依据。必要时应考虑多模式治疗干预,包括显微外科切除术、立体定向放射外科手术以及利用新兴分子靶点的进一步研究。
{"title":"Intermixed arteriovenous malformation and hemangioblastoma: case report and literature review.","authors":"Vincent Healy, Philip J O'Halloran, Mohammed B Husien, Ciaran Bolger, Michael Farrell","doi":"10.2217/cns-2020-0021","DOIUrl":"10.2217/cns-2020-0021","url":null,"abstract":"<p><p>We report the third presentation of an intermixed arteriovenous malformation and hemangioblastoma. The rare occurrence of the diagnostic histologic features of both a neoplasm and vascular malformation in a single lesion is more common in gliomas, as angioglioma, and is termed an 'intermixed' lesion. We review the literature concerning the developmental biology of each lesion, and potential interplay in the formation of an intermixed vascular neoplasm and vascular malformation. The roles of cellular origin, genetic susceptibility, favourable microenvironment, altered local gene expression and key regulatory pathways are reviewed. Our review supports angiography and genetic profiling in intermixed lesions to inform management strategies. Consideration should be given to multimodality therapeutic interventions as required, including microsurgical resection, stereotactic radiosurgery and further research to exploit emerging molecular targets.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/31/34/cns-09-66.PMC7737198.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38310457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A view on the landscape of breast cancer brain metastases. 乳腺癌脑转移的概况。
Q1 Medicine Pub Date : 2020-09-01 Epub Date: 2020-09-29 DOI: 10.2217/cns-2020-0013
Rachna Malani
Introduction to breast cancer & brain metastases & why subtypes matter Metastases to the central nervous system (CNS) are an unfortunate complication of breast cancer, second only to lung cancer [1–4]. The incidence of breast cancer brain metastases (BCBM) are approximated to be 5–16% in studies [1,5–7]; however, at autopsy the incidence is in fact much higher [1,6,8]. The development of BCBM can be associated with neurologic morbidity and augurs an inferior prognosis [9–11]. Moreover, BCBM are not limited to advanced stage disease, as the CNS is a site for relapse even in early stage breast cancer [5]. Presently, routine screening is not recommended, thus there is no precise understanding of CNS disease burden at diagnosis as typically BCBMs are captured due to symptoms and/or examination findings [6,8]. Steadily, this incidence has been increasing, in part due to advancements in systemic therapies which have improved survival; patients are living longer so as to develop BCBM as well as progress in radiographic techniques which have led to enhanced detection [1,2,5,7,9,12]. Certain patient and tumor characteristics have been shown to be associated with a higher risk of developing BCBM and these include younger age (<35 years), positive nodal status, ethnicity, presence of visceral metastases, estrogen receptor negative disease, HER2 disease, grade III tumors and tumor size [1,5,6]. In addition, the number of BCBM has prognostic relevance [6] as does the size of the BCBM and the patient’s performance status [4]. Ultimately, it is necessary to not view breast cancer as a single disease but as a group of diseases [2,12,13], as its subtypes are associated with varying patterns of metastatic spread and prognosis [8,14–16]. The different subtypes based on hormone receptor status and HER2 status are associated with a difference in incidence [11,17,18]. The time from diagnosis of the initial breast cancer to the development of BCBM is longer in patients with estrogen receptor positive (ER+) disease versus those with triple-negative breast cancer (TNBC) or HER2-positive cancer [11].
{"title":"A view on the landscape of breast cancer brain metastases.","authors":"Rachna Malani","doi":"10.2217/cns-2020-0013","DOIUrl":"https://doi.org/10.2217/cns-2020-0013","url":null,"abstract":"Introduction to breast cancer & brain metastases & why subtypes matter Metastases to the central nervous system (CNS) are an unfortunate complication of breast cancer, second only to lung cancer [1–4]. The incidence of breast cancer brain metastases (BCBM) are approximated to be 5–16% in studies [1,5–7]; however, at autopsy the incidence is in fact much higher [1,6,8]. The development of BCBM can be associated with neurologic morbidity and augurs an inferior prognosis [9–11]. Moreover, BCBM are not limited to advanced stage disease, as the CNS is a site for relapse even in early stage breast cancer [5]. Presently, routine screening is not recommended, thus there is no precise understanding of CNS disease burden at diagnosis as typically BCBMs are captured due to symptoms and/or examination findings [6,8]. Steadily, this incidence has been increasing, in part due to advancements in systemic therapies which have improved survival; patients are living longer so as to develop BCBM as well as progress in radiographic techniques which have led to enhanced detection [1,2,5,7,9,12]. Certain patient and tumor characteristics have been shown to be associated with a higher risk of developing BCBM and these include younger age (<35 years), positive nodal status, ethnicity, presence of visceral metastases, estrogen receptor negative disease, HER2 disease, grade III tumors and tumor size [1,5,6]. In addition, the number of BCBM has prognostic relevance [6] as does the size of the BCBM and the patient’s performance status [4]. Ultimately, it is necessary to not view breast cancer as a single disease but as a group of diseases [2,12,13], as its subtypes are associated with varying patterns of metastatic spread and prognosis [8,14–16]. The different subtypes based on hormone receptor status and HER2 status are associated with a difference in incidence [11,17,18]. The time from diagnosis of the initial breast cancer to the development of BCBM is longer in patients with estrogen receptor positive (ER+) disease versus those with triple-negative breast cancer (TNBC) or HER2-positive cancer [11].","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/cns-2020-0013","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38430874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Can 3D-CRT meet the desired dose distribution to target and OARs in glioblastoma? A tertiary cancer center experience. 3D-CRT能否满足胶质母细胞瘤靶区和OARs所需的剂量分布?三级癌症中心经验。
Q1 Medicine Pub Date : 2020-09-01 Epub Date: 2020-09-18 DOI: 10.2217/cns-2020-0010
Narendra Kumar, Srinivasa Gy, Chinna B Dracham, Treshita Dey, Renu Madan, Divya Khosla, Arun Oinum, Rakesh Kapoor

Aim: The purpose of the study is to perform a dosimetric analysis of the doses received by planning target volume and organ at risks in the postoperative glioblastoma by using 3D-conformal radiotherapy to a total dose of 60 Gy in 30 fractions. Materials & Methods: All patients received concurrent temozolomide every day, and this was followed by adjuvant temozolomide of 5 days of treatment per month. Results: More than 98% of patients were treated with a dose of 60 Gy. Doses were analyzed for the normal whole brain, tumor volume, as well as all the organs at risk. Conclusion: Given the grave prognosis and the limited survival of glioblastoma despite the best treatment available, makes 3D-conformal radiotherapy an equally acceptable treatment option.

目的:本研究的目的是对胶质母细胞瘤术后采用3d适形放射治疗,总剂量为60 Gy,分30份,计划靶体积和危险器官所接受的剂量进行剂量学分析。材料与方法:所有患者每天同时使用替莫唑胺,随后每月辅助使用替莫唑胺5天。结果:超过98%的患者接受60 Gy剂量的治疗。对正常全脑、肿瘤体积以及所有危险器官的剂量进行了分析。结论:考虑到胶质母细胞瘤的预后严重,尽管有最好的治疗方法,但其生存期有限,因此3d适形放疗是一种同样可接受的治疗选择。
{"title":"Can 3D-CRT meet the desired dose distribution to target and OARs in glioblastoma? A tertiary cancer center experience.","authors":"Narendra Kumar,&nbsp;Srinivasa Gy,&nbsp;Chinna B Dracham,&nbsp;Treshita Dey,&nbsp;Renu Madan,&nbsp;Divya Khosla,&nbsp;Arun Oinum,&nbsp;Rakesh Kapoor","doi":"10.2217/cns-2020-0010","DOIUrl":"https://doi.org/10.2217/cns-2020-0010","url":null,"abstract":"<p><p><b>Aim:</b> The purpose of the study is to perform a dosimetric analysis of the doses received by planning target volume and organ at risks in the postoperative glioblastoma by using 3D-conformal radiotherapy to a total dose of 60 Gy in 30 fractions. <b>Materials &</b> <b>Methods:</b> All patients received concurrent temozolomide every day, and this was followed by adjuvant temozolomide of 5 days of treatment per month. <b>Results:</b> More than 98% of patients were treated with a dose of 60 Gy. Doses were analyzed for the normal whole brain, tumor volume, as well as all the organs at risk. <b>Conclusion:</b> Given the grave prognosis and the limited survival of glioblastoma despite the best treatment available, makes 3D-conformal radiotherapy an equally acceptable treatment option.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/cns-2020-0010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38395395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary intradural Hodgkin lymphoma of the conus medullaris and cauda equina: case report. 原发性髓圆锥和马尾硬膜内霍奇金淋巴瘤1例。
Q1 Medicine Pub Date : 2020-09-01 Epub Date: 2020-09-29 DOI: 10.2217/cns-2020-0002
Timothy J Williamson, Michael Wang, Jonathan Clark, Julia Williams, Armin Drnda

Primary Hodgkin lymphoma of the central nervous system is an exceedingly rare condition with very few cases reported in the literature. Isolated intradural involvement of the spine is rarer still, with only two prior cases located in the extramedullary cervical and lumbosacral spine. We present a 48-year-old female who was presented with back pain, radiculopathy and a short history of sphincter disturbance and was subsequently found to have a lobulated homogenously enhancing exophytic lesion involving the conus medullaris and cauda equina on magnetic resonance imaging. Histopathological examination demonstrated the features of classic Hodgkin lymphoma. In this report, we present a case of primary intramedullary Hodgkin lymphoma involving the conus medullaris and cauda equina.

中枢神经系统的原发性霍奇金淋巴瘤是一种极为罕见的疾病,文献中报道的病例很少。孤立的硬膜内受累的脊柱仍然是罕见的,只有两个以前的病例位于髓外颈椎和腰骶椎。我们报告了一位48岁的女性,她表现为背痛、神经根病和短暂的括约肌障碍病史,随后在磁共振成像上发现了一个分叶状均匀增强的外生病变,涉及髓圆锥和马尾。组织病理学检查显示典型霍奇金淋巴瘤的特征。在此报告中,我们提出一例原发性髓内霍奇金淋巴瘤累及髓圆锥和马尾。
{"title":"Primary intradural Hodgkin lymphoma of the conus medullaris and cauda equina: case report.","authors":"Timothy J Williamson,&nbsp;Michael Wang,&nbsp;Jonathan Clark,&nbsp;Julia Williams,&nbsp;Armin Drnda","doi":"10.2217/cns-2020-0002","DOIUrl":"https://doi.org/10.2217/cns-2020-0002","url":null,"abstract":"<p><p>Primary Hodgkin lymphoma of the central nervous system is an exceedingly rare condition with very few cases reported in the literature. Isolated intradural involvement of the spine is rarer still, with only two prior cases located in the extramedullary cervical and lumbosacral spine. We present a 48-year-old female who was presented with back pain, radiculopathy and a short history of sphincter disturbance and was subsequently found to have a lobulated homogenously enhancing exophytic lesion involving the conus medullaris and cauda equina on magnetic resonance imaging. Histopathological examination demonstrated the features of classic Hodgkin lymphoma. In this report, we present a case of primary intramedullary Hodgkin lymphoma involving the conus medullaris and cauda equina.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/52/94/cns-09-52.PMC7546171.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38430873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, IDH1-mutant glioblastoma: a case report from a Phase I study. IDH1抑制剂Ivosidenib用于复发性IDH1突变胶质母细胞瘤患者:来自I期研究的病例报告
Q1 Medicine Pub Date : 2020-09-01 Epub Date: 2020-07-27 DOI: 10.2217/cns-2020-0014
Dalissa Tejera, Marina Kushnirsky, Sakir H Gultekin, Min Lu, Lori Steelman, Macarena I de la Fuente

Glioblastoma is the most common and aggressive primary brain tumor. Despite standard multimodality therapy, median overall survival remains poor with a 5-year survival rate of approximately 5% in most studies (range 4.7-13.0%). Strong interest in targeting IDH mutations has led to a variety of studies in both hematologic malignancies and solid tumors and to the approval of IDH inhibitors such as ivosidenib, an IDH1 inhibitor, in hematologic malignancies. Here, we present the first case study of a patient with a recurrent IDH1-mutant glioblastoma who experienced improved seizure control and radiographic stable disease for more than 4 years while treated with ivosidenib. Such findings support the further development of IDH inhibitors as single agents and/or in combination for the treatment of IDH-mutant glioma.

胶质母细胞瘤是最常见、侵袭性最强的原发性脑肿瘤。尽管标准的多模式治疗,中位总生存率仍然很低,大多数研究的5年生存率约为5%(范围为4.7% -13.0%)。针对IDH突变的强烈兴趣导致了血液恶性肿瘤和实体肿瘤的各种研究,并批准了IDH抑制剂,如IDH1抑制剂ivosidenib,用于血液恶性肿瘤。在这里,我们提出了第一例复发性idh1突变胶质母细胞瘤患者的病例研究,该患者在接受伊沃西迪尼治疗后,癫痫发作控制得到改善,放射学上病情稳定超过4年。这些发现支持进一步开发IDH抑制剂作为单一药物和/或联合治疗IDH突变胶质瘤。
{"title":"Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, <i>IDH1</i>-mutant glioblastoma: a case report from a Phase I study.","authors":"Dalissa Tejera,&nbsp;Marina Kushnirsky,&nbsp;Sakir H Gultekin,&nbsp;Min Lu,&nbsp;Lori Steelman,&nbsp;Macarena I de la Fuente","doi":"10.2217/cns-2020-0014","DOIUrl":"https://doi.org/10.2217/cns-2020-0014","url":null,"abstract":"<p><p>Glioblastoma is the most common and aggressive primary brain tumor. Despite standard multimodality therapy, median overall survival remains poor with a 5-year survival rate of approximately 5% in most studies (range 4.7-13.0%). Strong interest in targeting IDH mutations has led to a variety of studies in both hematologic malignancies and solid tumors and to the approval of IDH inhibitors such as ivosidenib, an IDH1 inhibitor, in hematologic malignancies. Here, we present the first case study of a patient with a recurrent <i>IDH1</i>-mutant glioblastoma who experienced improved seizure control and radiographic stable disease for more than 4 years while treated with ivosidenib. Such findings support the further development of IDH inhibitors as single agents and/or in combination for the treatment of <i>IDH</i>-mutant glioma.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/cns-2020-0014","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38204728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 18
Development of CNS metastases in breast cancer patients treated with curative intent: a case-control study. 以治愈为目的治疗的乳腺癌患者中枢神经系统转移的发展:一项病例对照研究。
Q1 Medicine Pub Date : 2020-09-01 Epub Date: 2020-09-18 DOI: 10.2217/cns-2020-0012
Katherine Chakrabarti, Leigh K Swartz, Anoop Gill, Fang Fang, Kelley M Kidwell, Aki Morikawa

Background: The aim of this study was to identify risk factors that may predispose breast cancer patients to the development of CNS metastases. Materials & methods: We conducted a matched case-control study of breast cancer patients treated with surgery with curative intent. A total of 71 cases and 71 controls were analyzed, matched by year of surgery. Results: In our multivariable model, positive lymph node status (odds ratio [OR]: 5.08; CI: 2.04-12.65), the use of neoadjuvant chemotherapy (OR: 6.02; CI: 2.06-17.57) and triple-negative breast cancer (OR: 5.44; CI: 1.99-14.90) were statistically significant predictors of the development of CNS metastases. Conclusion: Women with certain risk factors have an increased odds of developing CNS metastases and evaluation of utility in brain metastases screening should be considered.

背景:本研究的目的是确定可能使乳腺癌患者易发生中枢神经系统转移的危险因素。材料与方法:我们对接受手术治疗的乳腺癌患者进行了配对病例对照研究。共分析了71例病例和71例对照,并按手术年份进行匹配。结果:在我们的多变量模型中,淋巴结阳性状态(优势比[OR]: 5.08;CI: 2.04-12.65),使用新辅助化疗(OR: 6.02;CI: 2.06-17.57)和三阴性乳腺癌(OR: 5.44;CI: 1.99-14.90)是中枢神经系统转移发生的统计学显著预测因子。结论:具有某些危险因素的女性发生中枢神经系统转移的几率增加,应考虑评估脑转移筛查的效用。
{"title":"Development of CNS metastases in breast cancer patients treated with curative intent: a case-control study.","authors":"Katherine Chakrabarti,&nbsp;Leigh K Swartz,&nbsp;Anoop Gill,&nbsp;Fang Fang,&nbsp;Kelley M Kidwell,&nbsp;Aki Morikawa","doi":"10.2217/cns-2020-0012","DOIUrl":"https://doi.org/10.2217/cns-2020-0012","url":null,"abstract":"<p><p><b>Background:</b> The aim of this study was to identify risk factors that may predispose breast cancer patients to the development of CNS metastases. <b>Materials & methods:</b> We conducted a matched case-control study of breast cancer patients treated with surgery with curative intent. A total of 71 cases and 71 controls were analyzed, matched by year of surgery. <b>Results:</b> In our multivariable model, positive lymph node status (odds ratio [OR]: 5.08; CI: 2.04-12.65), the use of neoadjuvant chemotherapy (OR: 6.02; CI: 2.06-17.57) and triple-negative breast cancer (OR: 5.44; CI: 1.99-14.90) were statistically significant predictors of the development of CNS metastases. <b>Conclusion:</b> Women with certain risk factors have an increased odds of developing CNS metastases and evaluation of utility in brain metastases screening should be considered.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/cns-2020-0012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38395394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Automated histologic diagnosis of CNS tumors with machine learning. 基于机器学习的中枢神经系统肿瘤的自动组织学诊断。
Q1 Medicine Pub Date : 2020-06-01 Epub Date: 2020-06-30 DOI: 10.2217/cns-2020-0003
Siri Sahib S Khalsa, Todd C Hollon, Arjun Adapa, Esteban Urias, Sudharsan Srinivasan, Neil Jairath, Julianne Szczepanski, Peter Ouillette, Sandra Camelo-Piragua, Daniel A Orringer

The discovery of a new mass involving the brain or spine typically prompts referral to a neurosurgeon to consider biopsy or surgical resection. Intraoperative decision-making depends significantly on the histologic diagnosis, which is often established when a small specimen is sent for immediate interpretation by a neuropathologist. Access to neuropathologists may be limited in resource-poor settings, which has prompted several groups to develop machine learning algorithms for automated interpretation. Most attempts have focused on fixed histopathology specimens, which do not apply in the intraoperative setting. The greatest potential for clinical impact probably lies in the automated diagnosis of intraoperative specimens. Successful future studies may use machine learning to automatically classify whole-slide intraoperative specimens among a wide array of potential diagnoses.

当发现新的肿块累及大脑或脊柱时,通常会提示神经外科医生考虑活检或手术切除。术中决策在很大程度上取决于组织学诊断,这通常是在一个小样本被送到神经病理学家立即解释时确定的。在资源贫乏的环境中,神经病理学家的访问可能受到限制,这促使几个小组开发用于自动解释的机器学习算法。大多数尝试都集中在固定的组织病理学标本上,这并不适用于术中环境。对临床影响最大的可能在于术中标本的自动诊断。成功的未来研究可能会使用机器学习在广泛的潜在诊断中自动分类术中全切片标本。
{"title":"Automated histologic diagnosis of CNS tumors with machine learning.","authors":"Siri Sahib S Khalsa,&nbsp;Todd C Hollon,&nbsp;Arjun Adapa,&nbsp;Esteban Urias,&nbsp;Sudharsan Srinivasan,&nbsp;Neil Jairath,&nbsp;Julianne Szczepanski,&nbsp;Peter Ouillette,&nbsp;Sandra Camelo-Piragua,&nbsp;Daniel A Orringer","doi":"10.2217/cns-2020-0003","DOIUrl":"https://doi.org/10.2217/cns-2020-0003","url":null,"abstract":"<p><p>The discovery of a new mass involving the brain or spine typically prompts referral to a neurosurgeon to consider biopsy or surgical resection. Intraoperative decision-making depends significantly on the histologic diagnosis, which is often established when a small specimen is sent for immediate interpretation by a neuropathologist. Access to neuropathologists may be limited in resource-poor settings, which has prompted several groups to develop machine learning algorithms for automated interpretation. Most attempts have focused on fixed histopathology specimens, which do not apply in the intraoperative setting. The greatest potential for clinical impact probably lies in the automated diagnosis of intraoperative specimens. Successful future studies may use machine learning to automatically classify whole-slide intraoperative specimens among a wide array of potential diagnoses.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/cns-2020-0003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38099911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
期刊
CNS Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1